The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia - PubMed
4 hours ago
- #pediatric oncology
- #CAR T cell therapy
- #B-ALL
- CAR T cell therapy has shown remarkable success in treating relapsed and refractory B cell acute lymphoblastic leukemia (B-ALL) in children and young adults.
- Since FDA approval in 2017, real-world data confirm benefits even in complex populations like infants and children with Down syndrome.
- Despite success, nearly half of patients relapse, necessitating ongoing advancements in therapy.
- The introduction of blinatumomab has shifted treatment paradigms, requiring reevaluation of CAR T cell application.
- Future directions include earlier use of CAR T cells, novel constructs, improved toxicity mitigation, and better post-therapy surveillance.
- The research highlights the need for continued improvements to enhance outcomes for children, adolescents, and young adults with B-ALL.